HOME > BUSINESS
BUSINESS
- FoundationOne Approved as CDx for Retevmo in Japan: Chugai
March 1, 2024
- MSD Files Keytruda Plus Chemoradiotherapy for Cervical Cancer in Japan
March 1, 2024
- Otsuka, AN Ventures Hook Up on US$30 Million Investment
February 29, 2024
- Santen Seeks Japan Nod for Eye Drop Targeting Myopia
February 29, 2024
- Pfizer Submits Hemophilia Treatment Marstacimab in Japan
February 29, 2024
- Gilead Files Truvada for HIV Prevention in Japan
February 29, 2024
- Towa to Roll Out New WPP Strategy to Maintain NHI Prices of Key Medicines
February 28, 2024
- Takeda to Outsource Dengue Vaccine Production to India’s Biological E
February 28, 2024
- Mitsubishi Chemical Scraps Regenerative Medicine Unit
February 28, 2024
- Radicava’s Brazil Launch Set for February 29: Mitsubishi Tanabe
February 28, 2024
- Insmed Revs Up for Product Expansion in Japan, Arikayce Frontline Filing Set for 2026 with More to Follow
February 28, 2024
- Japan Drug Market Tops 11 Trillion Yen for 1st Time Driven by Oncologics: IQVIA
February 27, 2024
- Shionogi Seeks Japan Nod for Akili’s Therapeutic App for Kids with ADHD
February 27, 2024
- BMS Files Ulcerative Colitis Med Ozanimod in Japan
February 27, 2024
- Chugai Tapping Wearable to Objectively Gauge Pain, First Eyes Endometriosis Trial
February 26, 2024
- Novel Antibiotic Fetroja Approved in Taiwan: Shionogi
February 26, 2024
- Maruho’s China Subsidiary Now Up and Running
February 26, 2024
- Economic Terms for Obesity Drug Deal Disclosed by Lilly: Chugai
February 26, 2024
- As Wegovy Hits Japan Market, Novo Re-Stresses Need for Proper Use
February 26, 2024
- Astellas CTO Eager to “Democratize” Digital Tools to Boost Productivity
February 21, 2024
ページ
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
